Wed, Aug 20, 2014, 8:09 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • jacosa jacosa Nov 1, 2012 12:16 PM Flag

    Reaction to Nov 1, 2012 CC

    Sales were good enough. Presentation was good enough. It'll serve as a spacer to separate us from the atrocious previous CC. NOTHING could repair all that damage at once.

    Interesting observations, in no particular order: We [or I] learned that Incyte gets to choose which Lilly joint programs it wants to buy enhanced royalties in (for 30% of ongoing costs) AFTER seeing phase 2 results. Among new Jakafi patients, 30% asked their physicians about it based on information from other patients. While an extreme long shot, the imaginable nephropathy market is much larger than I realized. The pussyfooting around "other, more obvious, opportunities" says "cancer cachexia" to me; I hadn't thought about '050 in that light, but it makes sense.

    The biggest whoops I noticed was the answer on whether requirements for pre-approval are slowing Jakafi uptake. The confusion was fixed quickly, but the answer was still short of excellent (pre-approval is not the rate limiting step).

    The audiences that matter in controlling share price are buy-side analysts and portfolio-runners, both groups difficult to sample. My VERY limited feedback about the buy-siders is that they smell money in Incyte, but were scared off by the bad CC. Again, a good one doesn't cancel out the bad one, but it takes the edge off the fear. I have no feedback at all about portfolio runners, but if they stop getting the fearful vibes from their analysts, they are likely to short INCY a bit less.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
INCY
51.66-0.46(-0.88%)Aug 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.